Enzo Life Sciences, Inc.

Enzo Biochem, Inc.

Enzo Diagnostics, Inc.

Enzo Therapeutics, Inc.

Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.

Other

Enzo Bochem, Inc.

Enzo Therapeutics, Inc. C/o Enzo Biochem, Inc.

C/o Enzo Biochem, Inc.

Enzo Life Science, Inc. C/o Enzo Biochem Inc.

Elazar Rabbani

Donegan, James J.

Diamond, Paul

Elazar S Rabbani

Jannis G Stavrianopoulos

James J Donegan

Jack Coleman

Dakai Liu

Praveen Pande

Dean L Engelhardt

Marleen Walner

Yuejun Xiang

Wei Cheng

Dollie Kirtikar

Stanley Kline

Rajesh Khazanchi

Joshua Rabbani

Wayne Forrest Patton

Ian Hurley

Xiaofeng Li

Richard Jin

Juan Carcamo

Robert Nussenblatt

Riddhi Bhattacharyya

Yazhou Zhang

Norman E Kelker

Baoying Liu

Lai Wei

Yaron Ilan

Zaiguo Li

Paul Diamond

Robert G Pergolizzi

Jayanta Roy-Chowdhury

Kenneth H Johnston

Barbara E Thalenfeld

Vincenzo Enea

Guangrong Zhang

Jennifer June Brown

Sherry P Goltz

Israel Gotsman

Janes G Stavrianopoulos

Dean L Englehardt

James G Wetmur

Stan Kline

Samuel B Abrams

Paula J Olsiewski

Maurizio Mauro

Ante Tocilj

Norman E Keller

Richard Nussenblatt

James G Donegan

Yuanxing Liang

The invention provides chemical conjugates comprising a plurality of fluorescence quenching moieties conjugated to polymer and the use of such conjugates to quench the emission of fluorescence from emitters including macromolecular fluorescent emitters such as phycoerythrin.

Fluorescence quencher polymer conjugates and uses thereof

The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

Sphingosine pathway modulating compounds for the treatment of coronavirus infection

Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.

Assays for detecting modified compounds

The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

Sphingosine pathway modulating compounds for the treatment of cancers

The invention provides reduced background substrates, such as multi-well plates, for use in enzyme-linked immunosorbent assays (ELISAs) and other ligand-binding assays, and methods for making and using the same.

Reduced background immunoassay plates

The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and transforming growth factor beta, (TGF-&#x3b2;).

Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta

The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.

Affinity tag nucleic acid and protein compositions, and processes for using same

Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.

Multisignal labeling reagents and processes and uses therefor

The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.

Immunomodulatory pharmaceutical compositions

Growing community of inventors

New York, NY, United States of America

Elazar S Rabbani